Disulfiram 500 mg is a high-dose formulation of disulfiram, a medication used to discourage drinking by producing unpleasant physiological effects when alcohol is consumed. It blocks the enzyme aldehyde dehydrogenase, causing acetaldehyde to build up if alcohol is taken; that accumulation produces flushing, nausea, headache, palpitations, and other aversive symptoms intended to deter alcohol use.

500 mg is above the most commonly prescribed maintenance dose (often 250 mg daily). Some clinicians may use 500 mg for short periods or specific patients, but higher doses increase the risk of side effects and liver toxicity. Any dose decision should be made by a healthcare provider based on medical history and monitoring.

Disulfiram 500 mg is used in the management of alcohol dependence as part of a broader treatment plan to maintain abstinence. It is not a cure; it’s a deterrent that works best when combined with counseling, support, and medical supervision.

Disulfiram begins inhibiting aldehyde dehydrogenase shortly after absorption, so the aversive reaction can occur within hours if alcohol is consumed. The enzyme inhibition is essentially irreversible for the enzyme molecules affected, so effects can persist for up to about 1–2 weeks after stopping the drug until the body synthesizes new enzyme.

Only take disulfiram 500 mg if prescribed by a clinician. It’s oral and usually taken once daily; many prescribers start with a lower dose and monitor liver tests and tolerability. Avoid all alcohol-containing products (including some mouthwashes, cough syrups, and foods) and follow instructions about when to stop drinking before starting or after stopping the medication.

Common side effects include drowsiness, fatigue, metallic or garlic-like taste, headache, skin rash, and gastrointestinal upset. These effects may be more pronounced at higher doses such as 500 mg.

Serious concerns include liver toxicity (jaundice, dark urine, fatigue), severe neuropathy, psychosis or severe mood changes, and severe cardiovascular reactions when alcohol is consumed while taking disulfiram. Seek urgent care for signs of liver injury, severe confusion, numbness, or collapse.

No—consuming alcohol while taking disulfiram can produce a severe and potentially dangerous reaction, even with small amounts. Avoid all alcoholic beverages and products containing alcohol throughout treatment and for up to two weeks after stopping the drug; follow your clinician’s specific guidance.

Disulfiram 500 mg should not be used by people with severe heart disease, uncontrolled hypertension, psychosis, severe liver disease, pregnancy, or known hypersensitivity to disulfiram. Older adults and people on multiple medications require careful assessment and monitoring.

Disulfiram interacts with several drugs, including metronidazole and other nitroimidazoles (which can cause similar disulfiram-like reactions), certain anticoagulants like warfarin (altered bleeding risk), anticonvulsants like phenytoin (metabolism changes), and medications with hepatotoxic potential. Always review all prescriptions, OTC drugs, and supplements with your provider.

Disulfiram is generally avoided during pregnancy because of potential harm to the fetus; breastfeeding is also usually discouraged while taking disulfiram. Discuss alternatives and risks with an obstetrician and addiction specialist if pregnancy or breastfeeding is a concern.

Effectiveness depends heavily on adherence and patient motivation. When taken consistently and combined with psychosocial support and supervision, disulfiram can reduce drinking and support abstinence. Evidence shows benefits in select, well-monitored populations rather than as a stand-alone treatment for everyone.

Providers typically perform baseline and periodic liver function tests, assess for neuropathy and psychiatric symptoms, monitor adherence (pill counts, supervised dosing), and check for alcohol use or signs of disulfiram-alcohol reactions. More frequent monitoring is warranted at higher doses.

Most side effects are reversible when the medication is stopped early, but prolonged use or delayed detection of liver toxicity or neuropathy can lead to more lasting problems. Regular monitoring minimizes long-term risks.

Generic disulfiram is widely available by prescription; the 500 mg dose may be less commonly prescribed than 250 mg tablets and availability can vary by pharmacy. Cost tends to be low for generic formulations, but confirm with local pharmacies or insurance coverage.

Store disulfiram tablets at room temperature away from moisture and heat, in the original container and out of reach of children. Dispose of unused medication per local regulations and any instructions from your pharmacist.

If a dose is missed, follow the prescriber’s instructions—generally take the next scheduled dose and avoid doubling doses. Because of the serious consequences of drinking while on disulfiram, consult your clinician before resuming if you think you might have consumed alcohol.

Both doses contain the same active drug, but 500 mg carries a higher risk of adverse effects and liver toxicity than 250 mg without consistently proven superior benefit. Many clinicians prefer starting and maintaining lower doses to balance efficacy and tolerability; dose escalation is individualized and monitored.

Antabuse is a brand name for disulfiram and contains the same active ingredient as generic disulfiram 500 mg. Differences are typically limited to price, manufacturer, and packaging—therapeutic effects depend on the dose and monitoring rather than brand, but follow prescriber guidance on formulation and dosing.

Disulfiram (500 mg) deters drinking by causing aversive reactions if alcohol is consumed; naltrexone blocks opioid receptors to reduce alcohol’s rewarding effects. Naltrexone is often better tolerated and does not produce an aversive alcohol reaction, making it preferable for some patients; disulfiram works best for those motivated to avoid drinking and who accept the deterrent approach. Choice depends on clinical profile, comorbidities, and adherence strategies.

Acamprosate helps reduce cravings and supports abstinence by modulating glutamatergic neurotransmission and is typically dosed multiple times daily with minimal interaction with alcohol. Disulfiram is an aversive agent that produces immediate negative consequences if alcohol is consumed. Acamprosate may suit patients needing craving control, while disulfiram suits those seeking a strong deterrent—often both medications are considered within a broader treatment plan.

Combining medications can be useful in select cases to address both deterrence and craving, but increases complexity, potential interactions, and monitoring needs. Combinations should only be prescribed and supervised by a clinician experienced in addiction medicine, with clear plans for monitoring side effects and adherence.

Topiramate is sometimes used off-label to reduce alcohol consumption by modulating GABA/glutamate activity and can reduce craving and heavy drinking. Disulfiram’s aversive mechanism differs markedly—topiramate may be preferred for craving reduction and fewer social restrictions, while disulfiram is a behaviorally driven deterrent. Side-effect profiles and patient suitability vary.

Behavioral therapies (CBT, motivational interviewing, support groups) are foundational treatments for alcohol dependence and improve coping, relapse prevention, and motivation. Disulfiram 500 mg can complement behavioral therapy by adding a pharmacological deterrent, but medication alone is rarely sufficient; integrated care combining both approaches often yields the best outcomes.

Trials of disulfiram generally show benefit in certain populations, especially with supervised dosing, but results vary and adherence influences outcomes strongly. Higher doses like 500 mg are not consistently shown to be more effective than standard doses and may raise safety concerns; placebo-controlled benefits are typically linked to structured support rather than medication alone.

Nalmefene is an opioid receptor modulator used in some countries to reduce heavy drinking episodes by decreasing alcohol’s reinforcing effects. It differs from disulfiram’s aversive approach; nalmefene is taken as needed and focuses on harm reduction. Choice depends on patient goals (abstinence vs reduction), side effects, and regulatory availability.

Injectable naltrexone provides monthly, adherence-assured blockade of opioid receptors to reduce reward from alcohol; it avoids daily pill-taking issues and lacks disulfiram’s aversive reactions. Disulfiram 500 mg is a deterrent requiring daily adherence or supervision. The injectable option may suit patients who struggle with daily adherence or want a non-aversive pharmacologic approach.

The active ingredient is the same, but tablet strength differs. Therapeutic equivalence depends on the dose prescribed; lower-dose tablets can be adjusted by prescribers for individualized dosing while 500 mg tablets represent a larger single dose and may not be necessary for most patients. Discuss dosing strategy and tablet options with your pharmacist and prescriber.

Taking metronidazole with disulfiram can produce a disulfiram-like reaction (flushing, nausea, vomiting) in some people, so the combination is generally avoided or used with caution under medical supervision. Because of that interaction, clinicians often select alternative antibiotics or monitor closely if both are necessary.

Decisions should weigh medical history (liver disease, cardiac or psychiatric conditions), patient goals (abstinence vs reduction), likelihood of adherence or supervision, side-effect tolerance, pregnancy status, drug interactions, and access to psychosocial supports. A tailored plan developed with an addiction specialist and primary clinician yields the safest and most effective approach.

Discuss your alcohol use, medical history, and treatment goals with a licensed healthcare provider or addiction specialist. They can evaluate suitability for disulfiram 500 mg versus other medications or therapies, arrange baseline testing and monitoring, and design a safe, supervised treatment plan.